Michael Oh, MD, PhD

Dr. Oh is a clinical and translational thoracic oncologist focused on advancing immunotherapy approaches for lung cancer. His research seeks to understand how the tumor microenvironment shapes antitumor immune responses, with specific interests in myeloid signaling and tumor heterogeneity. Dr. Oh has been involved in studies of dendritic cell vaccines in nonsmall cell lung cancer and he's engaged in developing novel immunotherapeutic strategies.

Yang S, Multani A, Garrigues JM, Oh MS, Hemarajata P, Burleson T, Green NM, Oliai C,
Gaynor PT, Beaird OE, Winston DJ, Seet CS, Schaenman JM. Transient SARS-CoV-2 RNAdependent RNA polymerase mutations after remdesivir treatment for Chronic COVID-19 in
two transplant recipients: case report and intra-host viral genomic investigation. Microorganisms, 11(8): 2096 (2023).

*Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Huang ZL, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. J Immunother Cancer, 11(9): e006896 (2023).

Jensen A, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R, Liu B. Dendritic cell vaccination in non-small cell lung cancer: Remodeling the tumor immune microenvironment. Cells, 12(19): 2404 (2023).

*Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B. CXCL9/10-engineered dendritic cells promote T cell activation and enhances immune checkpoint blockade for lung cancer. Cell Rep Med, 5(4): 101479 (2024).

Oh MS, Abascal J, Rennels AK, Salehi-Rad R, Dubinett SM, Liu B. Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy. Cancers, 17(6): 1027 (2025).